Talazoparib

small molecule

Identifier: CI-DRUG-00000569
Entity page: /drug/talazoparib ↗
Edges: 231

Neighbours: 26 cancers2 genes3 variants10 trials13 approvals
Drawn: 54 of 54 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Talazoparib approved for …APPROVED_FOR18 of 13
→ approved for	Castration-Resistant Prostate Carcinomasubtype 2 source records aggregated	supports	FDA ORIG	Castration-Resistant Prostate Carcinoma	2	Regulatory	openfda	graph →
→ approved for	Malignant Breast Neoplasmcancer_family

Talazoparib predicts response to …PREDICTS_RESPONSE_TO3 of 3
← predicts response to	BRCA1 Loss-of-functionloss_of_heterozygosity 2 source records aggregated	sensitivity	B	Malignant Breast Neoplasm,Malignant Ovarian Neoplasm	2	Curated	civic	graph →
← predicts response to	BRCA2 Loss-of-function 2 source records aggregated	sensitivity	B	Malignant Breast Neoplasm,Malignant Ovarian Neoplasm	2	Curated	civic	graph →
← predicts response to	MRE11 Lossdeletion_cna	sensitivity	D	Malignant Endometrial Neoplasm	1	Curated	civic	graph →

Talazoparib predicts response to …PREDICTS_RESPONSE_TO3 of 3

← predicts response to

BRCA1 Loss-of-functionloss_of_heterozygosity

2 source records aggregated

sensitivity

Malignant Breast Neoplasm,Malignant Ovarian Neoplasm

Curated

Talazoparib targets …TARGETS2 of 2
→ targets	PARP1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	PARP2	—	INHIBITOR	—	1	Curated	chembl	graph →

Talazoparib investigated for …INVESTIGATED_FOR15 of 23show all (up to 200)
→ investigated for	Malignant Ovarian Neoplasmcancer 2 source records aggregated	supports	B	Malignant Ovarian Neoplasm	2	Curated	civic	graph →
→ investigated for	Malignant Breast Neoplasmcancer_family 2 source records aggregated	supports	B	Malignant Breast Neoplasm	2	Curated	civic	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Ovarian Neoplasmsubtype	unknown	3	Ovarian Neoplasm	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	3	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Malignant Endometrial Neoplasmsubtype	supports	D	Malignant Endometrial Neoplasm	1	Curated	civic	graph →
→ investigated for	Melanomacancer_family	unknown	2	Melanoma	1	Curated	chembl	graph →
→ investigated for	Bladder Neoplasmsubtype	unknown	2	Bladder Neoplasm	1	Curated	chembl	graph →
→ investigated for	Adrenal Gland Pheochromocytomasubtype	unknown	2	Adrenal Gland Pheochromocytoma	1	Curated	chembl	graph →
→ investigated for	Glioblastomasubtype	unknown	2	Glioblastoma	1	Curated	chembl	graph →
→ investigated for	Endometrial Neoplasmsubtype	unknown	2	Endometrial Neoplasm	1	Curated	chembl	graph →
→ investigated for	Angiosarcomasubtype	unknown	2	Angiosarcoma	1	Curated	chembl	graph →
→ investigated for	Lung Small Cell Carcinomasubtype	unknown	2	Lung Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Prostate Neoplasmsubtype	unknown	2	Prostate Neoplasm	1	Curated	chembl	graph →
→ investigated for	Renal Cell Carcinomasubtype	unknown	2	Renal Cell Carcinoma	1	Curated	chembl	graph →

Talazoparib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 91show all (up to 200)
→ investigated in trials for	Malignant Breast Neoplasmcancer_family 17 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 16 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasmcancer 10 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Neoplasmcancer 9 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Triple-Negative Breast Carcinoma 9 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Triple-Negative Breast Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Neoplasmcancer_family 8 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Castration-Resistant Prostate Carcinomasubtype 8 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Castration-Resistant Prostate Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Solid Neoplasm 8 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Solid Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemia 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinoma 5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Carcinoma 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Small Cell Carcinomasubtype 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Small Cell Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasm 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Fallopian Tube Neoplasm 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Fallopian Tube Neoplasm	4	Observed	clinicaltrials	graph →

Talazoparib studied in …STUDIED_INderived10 of 99show all (up to 200)
→ studied in	NCT05327010Phase 2 · active not recruiting Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial · 99 trials list this drug (33 active)	—	—	Malignant Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02693535Phase 2 · recruiting TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer · 99 trials list this drug (33 active)	—	—	Solid Neoplasm,Multiple Myeloma,Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04693468Phase 1 · recruiting Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial · 99 trials list this drug (33 active)	—	—	Malignant Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04982848withdrawn Korea Post Marketing Surveillance (PMS) Study of Talzenna® · 99 trials list this drug (33 active)	—	—	Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03964532Phase 1/Phase 2 · active not recruiting TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer · 99 trials list this drug (33 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05142241Phase 2 · active not recruiting Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial · 99 trials list this drug (33 active)	—	—	Malignant Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04019327Phase 1/Phase 2 · terminated A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer · 99 trials list this drug (33 active)	—	—	Prostate Adenocarcinoma,Prostate Neoplasm,Malignant Prostate Neoplasm+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT06844383Phase 2 · recruiting A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide · 99 trials list this drug (33 active)	—	—	Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04550494Phase 2 · active not recruiting Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations · 99 trials list this drug (33 active)	—	—	Malignant Solid Neoplasm,Breast Carcinoma,Malignant Pancreatic Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT02912572Phase 2 · active not recruiting Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer · 99 trials list this drug (33 active)	—	—	Malignant Endometrial Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths